The global transdermal drug delivery systems market is segmented on the basis of application, technology and geography. The application segment is further categorized into CNS, Pain Management, Hormone, Cardiovascular and Others. Transdermal patches for pain management and hormonal drug delivery dominate the market. Vivelle-dot and Climara are estrogen patches currently available in the market, offered by Novartis and Bayer HealthCare Pharmaceuticals, respectively. They are used in the delivery of estradiol for hormone replacement therapy. Based on technology, the global transdermal drug delivery systems market is segmented into Electroporation, Electric current, Lontophoresis, Radio Frequency, Microporation, Thermal, Mechanical arrays and Ultrasound. These technologies form an efficacious drug delivery system by improving the drug distribution pattern across the skin. Geographically, the global transdermal drug delivery systems market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominate the global market due to extensive R&D efforts and presence of numerous approved transdermal products.
This report offers the following benefits in particular:
In-depth coverage of the global transdermal drug delivery systems market including drivers, restraints and opportunities would help professionals to better understand market behavior
Detailed study of the strategies of key leaders, partnerships and acquisitions in the global transdermal drug delivery systems market would be informative for professionals in the corporate sector
Porter’s Five Forces analysis examines the competitive structure of the global transdermal drug delivery systems market and would assist market strategists in making decisions.
Pin-point analysis of geographic segments helps to identify opportunities for growth within the global transdermal drug delivery systems market
KEY MARKET SEGMENTS
The global transdermal drug delivery systems market is segmented into three major categories: application, technology and geography.
MARKET BY APPLICATION
MARKET BY TECHNOLOGY
MARKET BY GEOGRAPHY
1.1. REPORT DESCRIPTION
1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY
1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
22.214.171.124. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
126.96.36.199. Rising geriatric population
188.8.131.52. Increasing prevalence of chronic disorders
184.108.40.206. Rise in adoption of third-generation delivery systems
220.127.116.11. Side-effects of the systems
18.104.22.168. Emerging nations
CHAPTER 4 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM
4.1.1. Market size and forecast
4.2. PASSIVE DELIVERY SYSTEM
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
22.214.171.124. Matrix delivery system
126.96.36.199.1. Market size and forecast
188.8.131.52. Reservoir delivery system
184.108.40.206.1. Market size and forecast
4.3. ACTIVE DELIVERY SYSTEM
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
220.127.116.11. Structure-based drug delivery system
18.104.22.168.1. Market size and forecast
22.214.171.124. Electrically-based drug delivery system
126.96.36.199.1. Market size and forecast
188.8.131.52.2.1. Market size and forecast
184.108.40.206.3.1. Market size and forecast
220.127.116.11.4.1. Market size and forecast
18.104.22.168.1. Market size and forecast
CHAPTER 5 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2.1. Market size and forecast
5.3. HORMONE REPLACEMENT THERAPY
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5. MOTION SICKNESS
5.5.1. Market size and forecast
5.6. SMOKING CESSATION
5.6.1. Market size and forecast
5.7.1. Market size and forecast
CHAPTER 6 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast
6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast
6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast
6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. ACRUX LIMITED
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.1.6. Strategy share (%)
7.2. BAYER AG
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Strategy share (%)
7.3. BOEHRINGER INGELHEIM GMBH
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.3.6. Strategy share (%)
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Strategy share (%)
7.5. ECHO THERAPEUTICS, INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Strategy share (%)
7.6. ENDO PHARMACEUTICALS INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Strategy share (%)
7.7. GLAXOSMITHKLINE PLC
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Strategy share (%)
7.8. JOHNSON & JOHNSON
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Strategy share (%)
7.9. MYLAN N.V.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Strategy share (%)
7.10. NOVARTIS AG
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Strategy share (%)
Transdermal drug delivery systems are used to deliver drug through intact skin at a controlled rate into the systemic circulation. Increase in geriatric population and rise in number of patients suffering from chronic disorders, such as hypertension, diabetes, and angina, are expected to drive the market growth. Moreover, surge in adoption of new delivery system technologies, such as ultrasound, boosts the market growth. However, disadvantages of these delivery systems, such as irritation at the site of application and edema, are expected to impede the market growth.
The passive system segment is expected to dominate the market throughout the analysis period, owing to increase in the incidence of chronic disorders, such as hypertension. The active system segment is expected to register highest CAGR of 12.8% during the forecast period.
Key Findings of the Transdermal Drug Delivery Systems Market:
Reservoir system segment is projected to grow at a CAGR of 7.3% during the forecast period.
Matrix system contributed for nearly two-third share of the global passive transdermal drug delivery systems market, in 2016.
Structure-based drug delivery system segment is expected to register the highest CAGR of 13.3% during the analysis period.
Cardiovascular disorders segment is expected to grow at the highest CAGR of 10.8% during the forecast period.
France and Germany collectively contributed for more than one-third share of the European transdermal drug delivery systems market in 2016.
Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific transdermal drug delivery systems market in 2016.
Asia-Pacific is projected to register the highest CAGR of 10.1% during the forecast period, owing to improvement in healthcare infrastructures and rise in expenditures in emerging markets (India and China) to cater to the unmet medical needs. Technological advancements to develop cost-effective technologies in these nations offer a lucrative opportunity for the market growth.
The major companies profiled in the report includes Novartis AG, Johnson & Johnson, Mylan N.V., Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Acrux Limited, Echo Therapeutics, Inc., and Endo Pharmaceuticals Inc.
- Novartis AG
- Johnson & Johnson
- Mylan N.V.
- Boehringer Ingelheim GmbH
- Bayer AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
- Acrux Limited
- Echo Therapeutics Inc.
- Endo Pharmaceuticals Inc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.